SAN FRANCISCO Dec. 12 2011 PRNewswire Nektar Therapeutics Nasdaq NKTR announced today that the company has initiated its pivotal Phase 3 global clinical trial evaluating NKTR102 as a single agent in women with metastatic breast cancer.&160; NKTR102 is...
↧
Nektar Therapeutics Initiates Phase 3 BEACON Trial of NKTR102 in Women with Metastatic Breast Cancer
↧